PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ :		(11) International Publication Number: WO 93/01822
A61K 33/40, 31/19	A1	43) International Publication Date: 4 February 1993 (04.02.93)
(21) International Application Number: PCT/US (22) International Filing Date: 14 July 1992 (14605 28th Avenue North, Minneapolis, MN 55447.
(30) Priority data: PCT/US91/04979 15 July 1991 (15.07.91) (34) Country for which the regional or international application was filed:	V	(81) Designated States: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).
(71) Applicant (for all designated States except US): TECH CORPORATION [US/US]; 14605 28th North, Minneapolis, MN 55447 (US).	MIN h Aven	Published With international search report.
(72) Inventors; and (75) Inventors/Applicants (for US only): COSENTING C. [US/US]; 2435 Holly Lane, Plymouth, M (US). JANSEN, Walter, B. [US/US]; 4015 F Lane, Plymouth, MN 55441 (US). HALL, Rober [US/US]; 20175 Rhoda Avenue, Welch, MN (US). MARINO, Rosario, M. [CO/US]; 4847 V Road, Minnetonka, MN 55345 (US). HALL, Ki L. [US/US]; 20175 Rhoda Avenue, Wich, MN (US).	IN 554 Evergre rt, T., I 5508 Westgate mberly	

(54) Title: STABLE, ANTICORROSIVE PERACETIC/PEROXIDE STERILANT

(57) Abstract

Stable microbicides comprising hydrogen peroxide, peracetic acid, acetic acid and purified water substantially free of contaminants, sequestrants or stabilizers and having anticorrosive properties for metals used in surgical and dental instruments is disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT AU BB BE BF BC BJ BR CA CF CG CH CM CS DE DK ES	Austrai Barbados Belgium Burkina Faso Bulgaria Benin Brazil Canada Central African Republic Congo Switzerland Cöte d'Ivoire Cameroon Czechoslovakia Germark Spain	FI FR GA GB GN GR HU IE IT JP KP LI LK LU MC MG	Finland France Gabon United Kingdom Guinea Greece Hungary Ireland Italy Japan Democratic People's Republic of Korea Republic of Korea Liechtenstein Sri Lanka Lasembourg Monaco Madagascar	MI MN MW NI. NO PL RO RU SD SE SN TD TG US	Mali Mongolia Mauritania Malawi Netherlands Norway Polund Romania Russian Federation Sudan Sweden Senegal Soviet Union Chad Togo United States of America
--	---	--	--	---	---

1 STABLE, ANTICORROSIVE PERACETIC/PEROXIDE STERILANT 2 Background of the Invention

1. Field of the Invention

3

This invention relates generally to the field of microbicides. In particular, it relates to a stable microbicide having anticorrosive properties comprising a mixture of hydrogen peroxide, peracetic acid, acetic acid and purified water which is substantially free of contaminants or stabilizing and sequestrant type additives.

10 2. <u>Description of the Related Art</u>

11 Peracetic acid/peroxide containing compositions have a 12 long history of use as disinfectants and sterilizers due to 13 their microbicidal activities. However, peroxide containing 14 compositions are high-energy-state compounds and as such can be 15 considered thermodynamically unstable. Therefore, because there 16 is a strong tendency for these compositions to decompose in the 17 presence of multivalent metal ions, stabilizers are added. 18 Stabilizers may be agents such as sodium pyrophosphate, 19 phosphonic acid or chelating agents such as 8-hydroxyquinoline. 20 Stabilizers act by removing trace metals which accelerate the 21 decomposition of peroxides. Stabilizers also accelerate the 22 reaction between hydrogen peroxide and acetic acid to form peracetic acid. Therefore, for any given concentration of 23 24 hydrogen proxide and acetic acid, the addition of a stabilizer 25 increases the concentration at equilibrium of peracetic acid. 26 While conventional art compositions are stable due to 27 the use of added stabilizers, they are also highly corrosive to 28 the very metals they are designed to disinfect namely surgical 29 and dental instruments made of aluminum or brass, which 30 instruments are often plated with an ornamental or protective 31 layer of nickel or nickel and/or chromium. Additionally, 32 certain susceptible individuals often exhibit allergic reactions 33 to the conventional art formulations. Further, after prolonged 34 use these conventional art formulations often leave mineral-like 35 deposits on the metal instruments they sterilize.

PCT/US92/05877 WO 93/01822

A concentrated composition that contains no stabilizer 1 or sequestrant type additives that is both stable during storage 2 for prolonged periods of time and possesses anticorrosive 3 properties would be a decided advantage over these conventional 4 formulations. Further, a use-dilution formulation that may be 5 reused several times, is stable for relatively long periods in 6 the diluted form and possesses anticorrosive properties would be 7 a further advantage over conventional formulations. 8 9

Summary of the Invention

10

11

12

13

14

15

16

17

18 19

33

34

35

36

37

It is an object of the stable, anticorrosive concentrate and use-dilution microbicides in accordance with the present invention to solve the problems outlined above that has heretofore inhibited long-term storage and the anticorrosive sterilization of surgical and dental instruments. improved microbicide solutions not only have the desired stability but have been shown to have a significantly reduced corrosive effect on certain metals than those of conventional art mixtures of the peracetic acid/peroxide types known to the applicants.

In accomplishing the foregoing objectives, there has 20 been provided in accordance with the present invention a stable, 21 anticorrosive to surgical and dental metals concentrate 22 including peracetic acid, acetic acid, hydrogen peroxide and 23 purified water mixed in a ratio of from about one to eleven 24 parts total acid to one part hydrogen peroxide. The new 25 concentrate has from substantially about .001 ppm to 200 ppm, 26 more preferably from about .001 ppm to 100 ppm, and most 27 preferably from about .001 ppm to 10 ppm of added stabilizers, 28 such as phosphonic acids, sodium pyrophosphates and from about 29 .001 - 10 ppm of ionic and non-ionic contaminants such as 30 divalent and trivalent ions, with no added surfactants, such as 31 ethoxylated decyl alcohols, sulfonate and sulfate types. 32

In accordance with another aspect of the present invention, there has been provided a stable, anticorrosive to surgical and dental metals use-dilution formulation including a concentrate consisting essentially of at equilibrium peracetic acid, acetic acid, hydrogen peroxide and an aqueous diluent,

said concentrate characterized in having from about .001- 200

ppm of added stabilizers, from about .001-10 ppm of ionic and

nonionic contaminants and no added surfactants; and a purified

aqueous diluent; wherein the concentrate is diluted in the

aqueous diluent from about 20 to 40 times.

In accordance with still another aspect of the present

invention, there has been provided a process for preparing a sterilant concentrate as described above, including the steps of introducing from about 17% by weight to about 40% by weight hydrogen peroxide into a mixing drum, the hydrogen peroxide having from about .001-200 ppm of added stabilizers; blending thereinto from about 10% by weight to about 16% by weight acetic acid; and adding a purified aqueous diluent having from about .001-10 ppm of divalent and trivalent ions; wherein the equilibrium concentration includes from about 16-38% by weight hydrogen peroxide; from about 2.5-9% by weight acetic acid; from about 1.5-6.0% by weight peracetic acid; and an aqueous diluent and wherein the equilibrium concentration is characterized in having from about .001-200 ppm of added stabilizers, from about .001-10 ppm of ionic and nonionic contaminants and no added surfactants.

One of the advantages of the present invention is that the occasional allergic reactions of some individuals to the conventional art formulations is reduced. Another advantage of the present invention is that the presence of mineral-like deposits from the use of the solutions of conventional art formulations containing sequestrants or stabilizers is no longer found. Perhaps most importantly, however, the present invention allows metal instruments such as dental tools and surgical instruments to be sterilized with significantly reduced corrosivity as will be shown.

Further objects, features and advantages of the present invention will become apparent from the detailed description of the preferred embodiments, including the best mode, which follow.

PCT/US92/05877 WO 93/01822

Brief Description of the Drawings 1 Figure 1 is a chart of stability of the concentrated 2 microbicide against time where the initial formulation contained 3 4.1% by weight of peracetic acid and the storage temperature was 4 at ambient temperature of 22°C; 5 Figure 2 is a chart of stability of concentrated 6 microbicide where the initial formulation contained 4.5% by 7 weight of peracetic acid and the storage temperature was 35°C; 8 Figure 3 is a chart of stability of the concentrated 9 microbicide against time where the initial formulation contained 10 4.2% by weight of peracetic acid and the storage temperature was 11 50°C; 12 Figure 4 is a chart of stability of the concentrated 13 microbicide against time where the initial formulation contained 14 23% by weight of hydrogen peroxide and the storage temperature 15 was 22°C; 16 Figure 5 is a chart of stability of the concentrated 17 microbicide against time where the initial formulation contained 18 23% by weight of hydrogen peroxide and the storage temperature 19 20 was 35°C; Figure 6 is a chart of stability of the concentrated 21 microbicide against time where the initial formulation contained 22 23% by weight of hydrogen peroxide and the storage temperature 23 24 was 50°C; Figure 7 is a chart of stability of the concentrated 25 microbicide against time where the initial formulation contained 26 23% by weight of hydrogen peroxide, 4% by weight of peracetic 27 acid and 8.4% acetic acid and the solution was stored at ambient 28 29 temperature; Figure 8 is a chart of stability of the concentrated 30 microbicide against time where the initial formulation contained 31 23.8% by weight hydrogen peroxide and 4.47% by weight peracetic 32 acid and the solution was stored at ambient temperature; 33 Figure 9 is a chart of stability of the concentrated 34 microbicide against time where the initial formulation contained 35 23.8% by weight hydrogen peroxide and 4.47% peracetic acid and 36 the storage temperature was 35°C;

Figure 10 is a chart of stability of the concentrated 1 2 microbicide where the initial formulation contained 23.8% by 3 weight hydrogen peroxide and 4.47% by weight peracetic acid and 4 the storage temperature was 50°C; Figure 11 is a chart of stability of the concentrated 5 microbicide where the initial formulation contained 17.2% by 6 weight hydrogen peroxide and 0.0% by weight peracetic acid and 7 the solution was stored at ambient temperature; 8 9 Figure 12 is a chart of stability of the concentrated microbicide where the initial formulation contained 36.46% by 10 weight hydrogen peroxide and 0.0% by weight peracetic acid and 11 12 the solution was stored at ambient temperature; Figure 13 is a chart of stability of the concentrated 13 14 microbicide where the initial formulation contained 27.4% by 15 weight hydrogen peroxide and 5.6% by weight peracetic acid and the solution was stored at ambient temperature; 16 17 Figure 14 is a chart of stability of the concentrated 18 microbicide where the initial formulation contained 27.4% by 19 weight hydrogen peroxide and 5.3% by weight peracetic acid and 20 the solution was stored at 50°C. 21 Detailed Description of the Invention 22 Concentrate microbicide formulations in accordance 23 with the present invention possess the desirable property of a 24 long storage life without deleterious decomposition despite the 25 absence of conventional additions of stabilizers and 26 sequestrants as heretofore taught in the art. Additionally, 27 the concentrate compositions of the present invention are far 28 less corrosive to metals that are sterilized using the 29 compositions such as surgical and dental instruments. 30 contrast with conventional art formulations containing added 31 surfactants, sequestrants and other stabilizers where visible 32 evidence of corrosion of the metals appeared in one or two hours, formulations in accordance with the preferred embodiment 33

Manufacture of the preferred embodiment is effected by mixing a solution of hydrogen peroxide with acetic acid diluted

of the present invention visibly showed comparatively little

corrosion on the same metals during the same time period.

34

35

36

WO 93/01822 PCT/US92/0587?

with a purified aqueous diluent. The hydrogen peroxide is 1 selected from commercially available sources having low 2 concentrations of stabilizers, preferably .001 ppm to 200 ppm, 3 more preferably from about .001 ppm to 100 ppm, and most 4 preferably from about .001 ppm to 15 ppm of added stabilizers, 5 such as phosphonic acids, sodium pyrophosphates. Sources of 6 such hydrogen peroxide are available from FMC Corporation 7 (Philadelphia, PA). 8 In addition, the preferred embodiment in accordance 9 with the present invention preferably includes no contaminants. 10 Contaminants such as divalent and trivalent ions, principally, 11 iron, manganese, magnesium, nickel and cobalt, and undesirable 12 trace organics found in the manufacturing process, principally, 13 surfactants, acetone, methanol, ethanol, which are typically 14 present in conventional art formulations are found in the 15 present invention in amounts preferably from about 5-10 ppm and 16 most preferably from about .001-5 ppm in the final composition. 17 Referring to Table I, the preferred composition is 18 19 shown. TABLE I 20 After Equilibrium Initial Mixture 21 16-38% by wt. 17-40% by wt. 22 H_2O_2 2.5-9.0% by wt. 10-16% by wt. 23 HOAC 1.5-6.0% by wt. 24 0 HOOAC The concentrate microbicide in accordance with the 25 present invention may be formulated over a wide range of 26 concentrations of the active materials. After equilibrium the 27 concentrate microbicide may have as high as 38% by weight 28 hydrogen peroxide at equilibrium with the peracetic acid 29 concentration ranging from 1.5% to 6.0% as indicated in Table 1. 30 Since the concentrate when initially mixed contains no peracetic 31 acid and therefore is not used immediately, it is stored for 32 approxmately 19-20 days until the solution equilibrates and 33 peracetic acid is formed by the reaction of hydrogen peroxide 34

36 37

35

with acetic acid as illustrated in Reaction 1.

Reaction 1. 1 2 $CH_3CO_2H + H_2O_2$ $CH_3CO_3H + H_2O$ 3 The concentrate manufactured in accordance with the 4 present invention is stored and shipped in amber colored plastic bottles that have been thoroughly precleaned with purified water 5 to ensure no heavy metal contamination. Stability studies were 7 run at ambient (22°C), 35°C and 50°C to determine the stability of the concentrate over time at these temperatures. Data 8 9 regarding the relative stability of H2O2 and HOOAc in the concentrate composition and the concentrate itself are shown in 10 11 Figures 1-14. Acetic acid typically was not measured for stability since it is not one of the active ingredients of the 12 concentrate composition; in other words, acetic acid has no 13 14 microbicidal activity. As can be seen from Figures 1-15, the 15 solutions were very stable. 16 In addition to stability studies, corrosivity studies were run on the concentrate compositions, the results of which 17 may be seen by referring to Table IIA. Table IIB details the 18 19 results of the corrosivity run on conventional art formulations while Table IIC details the results of corrosivity testing on 20 21 the component parts of the conventional art formulation. Table 22 IID details the results of corrosivity studies run on the use-23 dilution formulations of the conventional art and several of the 24 preferred embodiments of the present invention. 25 Corrosivity studies were done using a variety of metal 26 They included naval brass 464 and aluminum 5052. The 27 coupons are commercially available from Metal Samples Company 28 (Munford, Al.) 29 Coupons were cleaned by the following methods to 30 remove all foreign debris and to ensure accurate results. 31 coupons were placed on edge in a 50% by weight solution of HCl 32 for two minutes at ambient temperature. Aluminum coupons were 33 placed on edge in concentrated nitric acid for three minutes at 34 ambient temperature. During all phases of the testing, coupons 35 were handled by gloved laboratory personnel to insure that the 36 coupons were not exposed to any foreign materials prior to

ê

```
placing them in the test solutions. All coupons are stamped with
 1
     a number to aid in identification. All coupons were air dried
 2
    under a ventilated hood and weighed prior to testing on a
 3
    Mettler AE 100 analytical balance. The weight was recorded as
 4
     the initial weight.
 5
               The exposure time of the coupons was .5 hours for
 6
    brass and 5 hours for aluminum when testing the concentrate
 7
    microbicide and 5 hours for brass and 1 week for aluminum when
 8
    testing the use-dilution formulation of the microbicide. The
 9
    coupons were tested in the test solutions indicated below at
10
     ambient temperature.
11
               Solution volumes of 70ml were dispensed into plastic
12
    disposable cups. The coupons were allowed to remain in solution
13
    for the times indicated above. After the time period had
14
    expired, the solution was discarded and the coupons were placed
15
    to dry, without rinsing, standing on edge in a ventilating hood.
16
    After drying for 30-60 minutes, the coupons were re-weighed.
17
    The difference between the initial weight and final weight (W)
18
    was used to calculated the corrosion rate as follows:
19
          Corrosion rate (mm/yr) = (K \times W)
20
                                      (A \times T \times D)
21
          K = a constant (8.76 \times 10^{-4})
22
          T = time of exposure in hours
23
         A = \text{area in } cm^{-2} (28.7 cm^{-2})
24
          W = weight loss in grams (initial weight - final weight)*
25
               *To correct for possible weight loss due to product
26
               removal, a "blank" coupon was weighed, cleaned by the
27
               procedure indicated above and weighed again.
28
          D = density in g/cm^{-3**}
29
               **Brass = 8.41 \text{ g/cm}^{-3}
30
                 Aluminum 5052 = 2.68 \text{ g/cm}^{-3}
31
32
                                 TABLE IIA
33
                                 <u>Titrations</u>
34
                                                      <u>HoAc</u>
                                     PAA
35
    Samples
                     H_2O_2
                                                      2.88%
                                     4.54%
                     38.8%
36
     1
                                     4.23%
                                                      3.27%
                     34.8%
     2
37
```

1	3	27.6%	5.0%	6.1%
2	4	27.4%	5.4%	· 6.2%
3	5	27.3%	5.5%	5.7%
·4	6	27.55%	5.03%	6.069
5	7	27.4%	5.4%	6.219
6	8	27.34%	5.51%	5.688
7	9	27.2%	5.72%	6.678
8	10	27.2%	5.70%	6.828
9	11	27.0%	5.62%	6.66%
10	12	. 27.0%	4.00%	5.71%
11	13	26.5%	4.14%	6.50%
12	14	22.5%	4.19%	7.848
13	15	22.5%	3.91%	8.1%
14	16	22.5%	3.86%	8.1%
15	17	19.6%	2.68%	8.62%
16	18	16.9%	1.66%	6.26%
17				
18			Corrosion	
19	Samples	Brass	Alumi	num
20	1	19.9	mm/yr 0.012	mm/yr
21	2	33.3	mm/yr .006	mm/yr
22	3	52.02	mm/yr .284	mm/yr
23	4	58.91	mm/yr .024	mm/yr
24	5	52.07	mm/yr .022	mm/yr
25	6	52.02	mm/yr .283	mm/yr
26	7	58.91	mm/yr .023	mm/yr
27	8	58.07	mm/yr .020	mm/yr
28	9	57.56	mm/yr .010	mm/yr
29	10	54.53	mm/yr .376	mm/yr
30	11	49.96	mm/yr .013	mm/yr
31	12	82.10	mm/yr .001	mm/yr
32	13	93.70	mm/yr .018	mm/yr
33	14	95.62	mm/yr 1.320	mm/yr
34	15	93.25	mm/yr .153	mm/yr
35	16	93.20	mm/yr .230	mm/yr
36	17	45.3	mm/yr .257	mm/yr

37

18

43.4 mm/yr .173 mm/yr

1	<u>Table IIB</u>				
2	Conventional Art Formulation				
3	•		<u>Titrat</u>	ion	
4		H_2O_2	<u>PAA</u>	HOAC	Phosphonic Acid
5					<u>Stabilizer</u>
6	Samples				
7	19	22.4%	3.96%	8.27%	1.0%
8	20	21.0%	4.3%	9.86%	1.0%
9			Corrosi	vity	·
10	<u>Samples</u>	<u>Bra</u>	<u>ss</u>	Alw	minum
11	19	295	.50 mm/yr	121	.63 mm/yr
12	20	295	.48 mm/yr	121	.65 mm/yr
13					
14			<u>Table</u>	IIC	
15		Corrosi	vity of C	omponent Pa	
16	<u>Samples</u>	Bra	ss		Aluminum
17	1% stabilizer	.58	6 mm/yr		.367 mm/yr
18	22.7% H ₂ O ₂	.52	8 mm/yr		.316 mm/yr
19	10.2% HoAc	.16	0 mm/yr		.167 mm/yr
20					
21			<u>Table</u>	IID	
22		<u>Use-c</u>	lilution Fo	ormulations	
23	Conventional Ar	t Bra	SS		<u>Aluminum</u>
24	3% Sample 19	23.	63 mm/yr		0.820 mm/yr
25	3% Sample 20	23.	84 mm/yr		0.747 mm/yr
26					
27	Present Inventi	on			
28	Sample X [27% H	₂ O ₂ ,			
29	5.3% PAA, 5.5%	Ac] 12.	77 mm/yr	0.43	37 mm/yr
30	Sample Y [37% H	₂ O ₂ ,			
31	4.8% PAA, 2.2%	Ac] 5.3	39 mm/yr	0.37	74 mm/yr
32	Sample Z [22% H	₂ O ₂ ,			
33	4.0% PAA, 7.0%	Acl 14.	63 mm/yr	0.44	11 mm/yr
34	a.ou lim, 1.ou		· 4		
35	* All use-dilut	ion sampl	es were pr	repared usin	ng 3% of the
36	concentrate for				
J 0	CONCENTRACE FOR			•	

In the present preferred form of the invention, the 1 2 concentrate is shipped in a small quantity in an amber colored plastic bottle together with a gallon of purified deionized 3 water. Before use, the concentrate of the preferred embodiment 4 is diluted from about 20 to 40 times, more preferably from about 5 25 to 35 times, and most preferably from about 30 to 33 times 6 7 with a purified aqueous diluent prepared as described below. 8 This results in a use-dilution formulation of approximately 3.0% 9 to 4.5% by volume of concentrate. Ordinary tap water is 10 generally unsuitable as a diluent because of contaminants, such 11 as divalent and trivalent ions, contained therein. If ordinary 12 tap water is used to dilute the concentrate, the shelf life of 13 the use-dilution formulation will likely be less than when the 14 purified aqueous diluent is used and corrosivity will increase 15 as the purity of the water decreases. The recommended shelf 16 life of the use-dilution microbicide is seven days. 17 Consequently, it may be used for several applications or reused 18 several times during that period of time with no change in the 19 stability or in the anticorrosive or sporicidal activity. 20 A purified aqueous diluent suitable for use in the 21 concentrate and use-dilution formulation in accordance with the 22 present invention is prepared in the following manner. Raw city 23 water is passed through an activated carbon bed containing 10 24 cubic feet of carbon in a 24 in. diameter fiberglass tank with a 25 2 in. diameter super flow head and a 2 in. diameter distributor. 26 The water is then passed through softening beds well 27 known in the art of water purification to remove calcium 28 chloride and magnesium. Suitable softening beds are available from Eco Water Systems (Woodbury, MN). The water is then passed 29 30 through a one micron polypropylene cloth sediment filter having 31 an efficiency rate of 93%. The cloth filter catches any 32 particulate matter remaining in the water that has a size 33 greater than 1_{u} . 34 The water then flows through an eight inch diameter 35 reverse osmosis membrane filter. The membrane filter is made 36 from a spirally wound polyamide sheet membrane and is 37 commercially available as Model No. BW-30 from Filmtec Co.

1 (Edina, MN). The water effluent has less than 5 ppm dissolved solids.
3 After the water is treated by passing it through the reverse osmosis membrane, it is circulated through an ultraviolet disinfection unit. The unit employs dual wave

5 ultraviolet disinfection unit. The unit employs dual wave 6 lengths at 185nm and 254nm and is rated at 99%.9 bacterial

7 reduction. A suitable commercially available unit is the

8 Aquafine U.V. Water Sterilizer, CLS-4R (Aquafine Corp, Valencia,

9 CA.)

10 Post-UV light treatment, the water flows through an anion exchange resin bed and a cation exchange resin bed. The anion exchange resin bed is a strongly basic anion exchange resin based on a styrenedivinylbenzene copolymer matrix. Its exchange capacity is derived from the N•(CH₃)₂H₄OH

15 (dimethylethanolamine) group. Anion exchange resin bed capable

16 of purifying the aqueous diluent in accordance with the present

17 invention may be purchased from Sybron Chemicals Inc

18 (Birmingham, N.J.) under the trade name IONAC ASB-2. The cation

19 exchange resin bed is a bead-form, standard crosslinked,

20 polystyrene sulfonate cation exchange resin with a capacity of

21 1.4 mEq/ml for further demineralization. Treated water is

22 stored in a 1000-5000 gallon tank. Resistivity is constantly

23 measured and maintained at 17-17.5 mOhms.

Prior to using the above manufactured water in the concentrate mixtures or use-dilution formulations in accordance with the present invention, the water is tested for pyrogen, yeast, molds and bacteria by the following methods.

Pyrogen Testing. Five milliliters of sterile water is pipetted into a vials of endotoxin, commercially available as endotoxin from E. coli strain 055.B5 from Whittaker Bioproducts, Inc. (Walkersville, MD). Five and two-tenths milliliters of sterile water is pipetted into a vial of lysate, commercially available as Pyrogen T from Whittaker Bioproducts. One hundred lambda of the reconstituted lysate is then pipetted into disposable conical tubes. The diluted lysate has a sensitivity

35 disposable conical tubes. 36 of 0.06 endotoxin units.

37

24

25

26

27

28

29

30

31

32

33

1 Serial dilutions of the reconstituted endotoxin

- 2 ranging from 500 picograms/ml to 12.5 picograms/ml are prepared.
- 3 Positive controls are set up by pipetting 100 lambda of each of
- 4 the above prepared dilutions of endotoxin into a conical tube
- 5 containing the lysate. Tubes are mixed and placed in a 370
- 6 heating block for one hour ± two minutes. Triplicate samples of
- 7 100 lambda each of ultra-pure deionized water as manufactured in
- 8 accordance with the procedure disclosed herein are added to the
- 9 lysate tubes and incubated at 37°C for one hour. A gelled tube
- 10 indicates the presence of endotoxin.
- 11 Yeast, Molds and Bacteria Testing
- 12 Water used in the manufacture of the concentrate
- 13 microbicide and in the use-dilution formulation is tested for
- 14 the presence of microbes using a filter membrane technique.
- 15 Samples are collected aseptically in sterile 10ml test tubes at
- 16 the source. Five milliliters of sample is transfered into a
- 17 100ml filter housing. A vacuum is applied to the filter housing
- 18 to facilitate filtration. The lower housing is removed and the
- 19 filtrate is decanted. The filter membrane is aseptically
- 20 removed and placed in a tryptone glucose yeast agar plate (DiMed
- 21 Corporation, St. Paul, MN) for measuring bacterial growth and
- 22 potato dextrose agar plates (DiMed Corporation, St. Paul, MN)
- 23 for measuring yeast and mold growth. The media plate is
- 24 covered, inverted and incubated at 35°C for two days for
- 25 bacteria and at 22°C for seven days for yeasts and molds.
- 26 Results are reported as the number of colony forming units per
- 27 five milliliters of sample size.
- 28 EXAMPLES
- 29 Example 1
- 30 All mixing drums and tanks were thoroughly cleaned
- 31 using purified water. Sixty percent by weight of purified water
- 32 was added to a cleaned mixing tank at ambient temperature.
- 33 Bacterial testing and yeast and molds testing of the water used
- 34 in manufacturing the concentrate was reported as 0 colony
- 35 forming units per five milliliters of sample for both tests. An
- 36 air driven drum pump was turned on to start recirculation of the
- 37 batch. Fourteen percent by weight of acetic acid was added to

- 1 the mixing tank containing the deionized water. After the
- 2 acetic acid was added, the batch was covered and recirculated
- 3 for one hour. Using an air driven drum pump, 26% by weight of
- 4 hydrogen peroxide was added into the mixing tank and the cover
- 5 replaced. The composition was recirculated for two hours after
- 6 all chemicals were added. After two hours, the recirculating
- 7 pump was stopped. The concentrate was dispensed into clean 55
- 8 gallon drums for storage and equilibrated for 19 days. After 19
- 9 days from the production date, a sample was taken from the
- 10 concentrate batch and the concentration was determined to be
- 11 22.5% H_2O_2 , 3.96% peracetic acid, and 8.1% acetic acid.

12 Microbicidal Effectiveness

- A 3.0% solution of the concentrate microbicide
- 14 manufacture in Example 1 was tested for sporicidal activity
- 15 according to the methods outlined in the Official Methods of
- 16 Analysis of the Association of Official Analytical Chemists (K.
- 17 Helrich 15th ed. 1990) (966.04 pp. 141-142), the text of which
- 18 is hereby specifically incorporated by reference.
- 19 Briefly, cultures of two sporoformer organisms,
- 20 Bacillus subtilis ATCC 19659 and Clostridium sporogenes ATCC
- 21 3584 were grown in the appropriate medium. Each organism was
- 22 used to contaminate two types of carriers, namely, silk suture
- 23 and porcelain penicylinders. The carriers were dried for a
- 24 minimum of 24 hrs. under vacuum. Carriers were tested for acid
- 25 resistance and viability. Five carriers were placed in test
- 26 tubes containing 10 mL. of test solution, and exposed for 30
- 27 min. at 50°C. Following contact, carriers were neutralized in
- 28 thioglycollate medium and incubated for 21 days at 37°C. If no
- 29 growth was observed after 21 days, the test tubes were heat
- 30 shocked for 20 minutes at 80°C to activate any remaining spores
- 31 and incubated for 72 hrs. at 37°C. For chemical sterilant
- 32 claims, no survival of any organism/spore can be tolerated for
- 33 qualification of the solution by the U.S. Environmental
- 34 Protection Agency as a sterilant. The results of the sporicidal
- 35 testing of the concentrate microbicide in accordance with the
- 36 microbicide prepared in Example 1 are as follows:

1	Lot	Org. Carrier	Titer	Resistance	#Survivors/
2		٠			#Tested
3	2M004	.Cl.sp. Suture	10-6	20 min.	0/60
4	2M004 .	Cl.sp. Cylinder	10-5	5 min.	0/60
5	2M004	B. sub.suture	10-4	20 min.	0/60
6	2M004	B. sub.Cylinder	10-4	2 min.	0/60

7

The results of the AOAC procedure reference test shows that 8 9 the microbicide of the invention, in addition to being stable, is effective as a sterilant. 10

11 Corrosivity of the solution of Example 1 was tested. The results appear as Sample 15 in Table IIA. 12

13

Example 2

14 All mixing drums and tanks were thoroughly cleaned 15 using purified water. 23.3% by weight of purified water was 16 added to a cleaned mixing tank at ambient temperature. 17 Bacterial testing and yeast and molds testing of the water used 18 in manufacturing the concentrate was reported as 0 colony 19 forming units per five milliliters of sample for both tests. An 20 air driven drum pump was turned on to start recirculation of the 21 22 16.7% by weight of acetic acid was added to the mixing tank containing the purified water. After the acetic acid was 23 added, the batch was covered and recirculated for one hour. 24 Using an air driven drum pump, 40.0% by weight of hydrogen 25 peroxide was added into the mixing tank and the cover replaced. 26 The composition was recirculated for two hours after all 27 chemicals were added. After two hours, the recirculating pump 28 was stopped. The concentrate was dispensed into clean 55 gallon 29 30 drums for storage. After 19 days from the production date, the batch was adjusted to a hydrogen peroxide level of 36.5% and a 31 peracetic acid level of 4.5% by adding water and hydrogen 32 peroxide. The solution was allowed to equilibrate for an 33

36 37

34

35

additional 33 days. A sample was taken from the concentrate

peroxide, 4.31% peracetic acid and 2.88%.

batch and the concentration was determined to be 36.65% hydrogen

The results of the sporicidal testing of a 3% solution of the concentrate microbicide in accordance with the microbicide prepared in Example 2 are as follows:

4	Lot	Org. Carrier	Titer	Resistance	#Survivors/
5					#Tested
6	2008-2a	Cl.sp. Suture	10-6	20 min.	0/60
7	2008-2a	Cl.sp. Cylinder	10-6	10 min.	0/60
8	2008-2a	B. sub.suture	10-4	10 min.	0/60
9	2008-2a	B. sub.Cylinder	10-4	2 min.	0/60

10

The concentrate prepared in accordance with Example 2 was tested for corrosivity. The results are shown in Table IIA as Sample 2.

14 Example 3

Using the method set forth in Examples 1 and 2, 7.74% 15 by weight purified water was added to 17.12% by weight H_2O_2 and 16 8.143% by weight HOAc. Bacterial testing and yeast and molds 17 testing of the water used in manufacturing the concentrate was 18 reported as 0 colony forming units per five milliliters of 19 sample for both tests. After mixing for the specified time 20 periods, the concentrate was allowed to stand for 19 days and a 21 sample was taken to determine the content of H_2O_2 and HOOAc. 22 The final concentration was determined to be 16.86% by weight 23 $\rm H_2O_2$, 1.66% peracetic acid and 6.26% acetic. The solution was 24

26	Lot	Org. Carrier	Titer	Resistance	#Survivors/
27					#Tested
28	2028-1	Cl.sp. Suture	10-5	10 min.	0/60
29	2028-1	Cl.sp. Cylinder	10-6	10 min.	0/60
30	2028-1	B. sub.suture	10-4	10 min.	0/60
31	2028-1	B. sub.Cylinder	10-4	2 min.	0/60

found to have microbicidal activity as follows:

32

25

Corrosivity was tested and the results are detailed in Table IIA as Sample 18.

35 While the preceding compositions in accordance with 36 the invention are the preferred form it is to be understood that 37 concentrate formulations may be within the ranges given and

1 still provide the advantages of the invention. Those skilled in

- 2 the art may recognize other equivalents to the specific
- 3 embodiments described herein which equivalents are intended to
- 4 be encompassed by the appended claims.

1	We claim:
2	1. A stable, anticorrosive to surgical and dental
3	metals concentrate consisting essentially of at equilibrium
4	peracetic acid, acetic acid, hydrogen peroxide and an aqueous
5	diluent, said concentrate characterized in having from about
6	.001-200 ppm of added stabilizers, from about .001-10 ppm of
7	ionic and nonionic contaminants and no added surfactants.
8	 The concentrate in accordance with Claim 1
9	wherein the concentration of added stabilizer is from about .001-
10	100 ppm.
11	 The concentrate is accordance with Claim 1
12	wherein the concentration of added stabilizer is from about .001-
13	10 ppm.
14	4. The concentrate of Claim 1 wherein the
15	equilibrium composition comprises:
16	a) H_2O_2 16 to 38% by weight;
17	b) HOAc 2.5 to 9.0% by weight;
18	c) HOOAc 1.5 to 6.0% by weight; and
19	 d) the balance is a purified aqueous diluent.
20	 The concentrate in accordance with Claim 4
21	wherein the concentration of added stabilizer is from about .001-
22	100 ppm.
23	6. The concentrate in accordance with Claim 4
24	wherein the concentration of added stabilizer is from about .001-
25	10 ppm.
26	 The concentrate in accordance with Claim 1
27	wherein the equilibrium concentration comprises:
28	a) H_2O_2 23 to 24% by weight;
29	b) HOAc 9 to 10% by weight;
30	c) HOOAc 4 to 6% by weight; and
31	 d) the balance is a purified aqueous diluent.
32	The concentrate in accordance with Claim 7
33	wherein the concentration of added stabilizer is from about .001-
34	100 ppm.
35	 The concentrate in accordance with Claim 7
36	wherein the concentration of added stabilizer is from about .001-

37


10 ppm.


1 10. A method of formulating a stable, anticorrosive 2 to surgical and dental metals concentrate microbicide comprising 3 the steps of:

- a) blending hydrogen peroxide, acetic acid and a purified aqueous diluent to result in a solution which at equilibrium has from about .001-200 ppm added stabilizers, from about .001-10 ppm of ionic and nonionic contaminants and no added surfactants.
- 9 11. A method of formulating a stable, anticorrosive 10 to surgical and dental metals concentrate microbicide comprising 11 the steps of:
- a) introducing from about 17% by weight to about 40% by weight hydrogen peroxide into a mixing drum, said hydrogen peroxide having from about .001-200 ppm of added stabilizers; and
- b) blending thereinto from about 10% by weight to about 16% by weight acetic acid; and
- c) adding a purified aqueous diluent having from about .001-10 ppm of divalent and trivalent ions;
- 20 wherein the equilibrium concentration comprises:
- i) from about 16-38% by weight hydrogen peroxide;
- ii) from about 2.5-9% by weight acetic acid;
- 23 iii) from about 1.5-6.0% by weight peracetic acid;
- 24 and
- 25 iv) an aqueous diluent
- 26 wherein said equilibrium concentration is characterized in
- 27 having from about .001-200 ppm of added stabilizers, from about
- 28 .001-10 ppm of ionic and nonionic contaminants and no added
- 29 surfactants.
- 30 12. A stable, anticorrosive to surgical and dental 31 metals use-dilution microbicide comprising:
- 32 a) a concentrate consisting essentially of at
- 33 equilibrium peracetic acid, acetic acid, hydrogen peroxide and
- 34 an aqueous diluent, said concentrate characterized in having
- 35 from about .001- 200 ppm of added stabilizers, from about .001-
- 36 10 ppm of ionic and nonionic contaminants and no added
- 37 surfactants; and
- b) a purified aqueous diluent;

1	wherein said concentrate is diluted in said aqueous diluent from
2	about 20 to 40 times.
3	
4	
5	


Fig. 1







2/7


Fig. 3





3/7 Fig. 5





4/7 Fig.7






Fig.8



5/7. Fig.9



6/7







Fig.11



7/7 **Fig.1**3





Fig.14



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/05877

			4.7
A. CLASSIFICATION OF SUBJE IPC(5): A61K 33/40; A61K 31/19 US CL: 424/616; 514/55 According to International Patent Classi		ssification and IPC	·
B. FIELDS SEARCHED			
Minimum documentation searched (class U.S. :	ification system followed by classific	cation symbols)	
Documentation searched other than minin	num documentation to the extent that	such documents are included	in the fields scarched
Electronic data base consulted during the	; international search (name of data t	base and, where practicable	, search terms used)
C. DOCUMENTS CONSIDERED	TO BE RELEVANT		
Category* Citation of document, w	vith indication, where appropriate, of	f the relevant passages	Relevant to claim No.
Y Chemical Abstract, volume microbiocides containing habstract No. 199231u.	110, NO. 22 issued 29 May 1989, sydrogen peroxide and acetic acid a	L. COSENTINO, "Stable and peracetic acid". See	1-12
Further documents are listed in the	continuation of Box C. S	See patent family annex.	
Special categories of cited documents:			
A* document defining the general state of the	art which is and considered	r document published after the inter and not in conflict with the applicat sciple or theory underlying the inve	ion but cited to understand the
to be part of particular relevance. E* earlier document published on or after the		ument of particular relevance; the	i i
L' document which may throw doubts on pr cited to establish the publication date of	riority claim(s) or which is who	udered novel or cunnot be consider in the document is taken alone	ed to involve an inventive step
special reason (as specified) O* document referring to an oral disclosure means	, use, exhibition or other com	ument of particular relevance; the sidered to involve an inventive a bined with one or more other such ag obvious to a person skilled in the	step when the document is documents, such combination
P* document published prior to the internation the priority date claimed	sel filing data but later than	ement member of the same patent fi	t
Date of the actual completion of the intern	ational search Date of maili	ing of the international sear	ch report
Name and mailing address of the ISA/ Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized of ZOHREH	flicof Landi L	a de
Sessimile No. NOT APPI ICARI E	Talanhana M.	. /702\ 209 1225	10 -

Form PCT/ISA/210 (second sheet)(July 1992)*